Metastatic breast cancer remains the leading cause of breast-cancer mortality, and the peptide programs in development span three modalities: peptide-and-cell immunotherapies, peptide-drug conjugates, and peptide cancer vaccines. BriaCell's Bria-IMT — a whole-cell allogeneic immunotherapy combined with checkpoint inhibitor — is in Phase 3 in heavily pretreated metastatic breast cancer patients who have failed antibody-drug conjugate, checkpoint, and CDK4/6 inhibitor therapy. The trial added Penn Medicine's Abramson Cancer Center, Smilow Cancer Hospital at Yale New Haven, and the Los Angeles Cancer Network as clinical sites in May 2026, and the program carries six accepted ASCO 2026 abstracts covering 12- and 24-month survival, quality of life, and circulating-tumor-cell biomarker work.
On the peptide-drug-conjugate side, a Molecular Therapy Oncology 2026 paper reported a Fibulin-4-targeting peptide that selectively killed metastatic breast cancer cells in mouse models, also serving as an imaging probe for detection. The Fibulin-4 target is significant because triple-negative metastatic disease leaves a substantial therapy gap that HER2 and hormone-receptor targeting do not close.
Stories here cover the Bria-IMT pivotal trial, Fibulin-4 and other peptide-drug-conjugate programs, and the broader peptide-vaccine pipeline. See #bria-imt, #briacell, and #peptide-drug-conjugate.
BriaCell's three June 1 poster presentations moved past the previously reported 16.6-month Phase 2 median overall survival to the first blinded data from the pivotal Phase 3 Bria-ABC study: sustained quality of life despite advanced disease and a meaningful TWiST (time without symptoms or toxicity) result. Biomarker tracking continued, with stable or decreasing CAML counts correlating with better progression-free survival in 60% of evaluable patients. The Phase 3 regimen starts the checkpoint inhibitor in Cycle 1 and uses a Bria-IMT formulation without interferon-gamma.
BriaCell Therapeutics priced a registered direct offering of 1,449,300 common shares at $3.25 each for gross proceeds of about $4.7 million, with ThinkEquity as sole placement agent. The company plans to use proceeds for working capital, general corporate purposes, and advancing its pipeline. The raise lands days after BriaCell reported 16.6-month median overall survival for its Bria-IMT cell-based immunotherapy in heavily pretreated metastatic breast cancer at ASCO 2026.
BriaCell's ASCO 2026 poster presentations added a biomarker finding beyond the headline 16.6-month median overall survival for Bria-IMT. In an ongoing analysis of heavily pretreated metastatic breast cancer patients, 65% showed stability or a drop in Cancer-Associated Macrophage-Like cells (CAMLs) — circulating cells in the blood that reflect tumor activity — and that change significantly correlated with better progression-free survival. The CAML biomarker offers a potential early blood-based readout of Bria-IMT response, which matters for an immunotherapy where conventional imaging can lag the immune response. BriaCell's six ASCO 2026 data items (three posters, three publication-only abstracts) cover the pivotal Phase 3 Bria-ABC study of Bria-IMT plus checkpoint inhibitor plus further Phase 2 analyses. Bria-IMT is a whole-cell allogeneic peptide-and-cell immunotherapy in heavily pretreated metastatic breast cancer that has failed ADC, checkpoint, and CDK4/6 inhibitor therapy. The biomarker work supports patient selection and response monitoring as the program advances toward accelerated-approval discussions.
BriaCell's formal post-ASCO 2026 press release Friday morning specified the headline number from yesterday's abstract release. Final Phase 2 median overall survival with Bria-IMT plus checkpoint inhibitor reached 16.6 months in heavily pretreated metastatic breast cancer patients using the Phase 3 formulation — a substantial improvement over historical post-ADC, post-CPI, post-CDK4/6-failure populations where median OS typically runs 8-10 months. The release also specified positive quality-of-life data from the ongoing Phase 3 study and biomarker analyses confirming the predictors of anti-cancer response observed in Phase 2 carry forward into the Phase 3 cohort. The three poster presentations plus three publication-only abstracts at ASCO 2026 (May 29-June 2) will detail 12- and 24-month survival, treatment tolerability, and circulating-tumor-cell biomarker work. The 16.6-month median OS sets the bar BriaCell needs to clear or beat in the ongoing Phase 3 to support its accelerated approval ambitions.
BriaCell released final randomized Phase 2 Bria-IMT survival and quality-of-life data at ASCO 2026 alongside biomarker analyses from the ongoing Phase 3 study. Bria-IMT — a whole-cell allogeneic peptide-and-cell immunotherapy combined with checkpoint inhibitor — has been studied in heavily pretreated metastatic breast cancer patients who have failed antibody-drug conjugate, checkpoint, and CDK4/6 inhibitor therapy. The Phase 2 data set covers 12- and 24-month survival, treatment tolerability, and circulating-tumor-cell biomarker work. The Phase 3 program added Penn Medicine's Abramson Cancer Center as a site on May 13, joining Smilow Cancer Hospital at Yale New Haven and the Los Angeles Cancer Network. The six-abstract BriaCell package at ASCO 2026 — three poster presentations and three publication-only abstracts — establishes the company as the largest peptide-immunotherapy presence at this year's meeting.
BriaCell announced May 14 it has completed manufacturing of clinical supplies for Bria-PROS+, the company's prostate cancer cell-based immunotherapy candidate, positioning the program for an IND filing and Phase 1/2 initiation later in 2026. On May 13, BriaCell added Penn Medicine's Abramson Cancer Center as a clinical site for the pivotal Phase 3 Bria-IMT metastatic breast cancer study, bringing the trial-site network to include Smilow Cancer Hospital at Yale New Haven and Los Angeles Cancer Network. The two announcements come ahead of BriaCell's six accepted ASCO 2026 abstract presentations on Bria-IMT and Bria-OTS+ in metastatic breast cancer, scheduled for the May 29-June 2 Chicago meeting. The May 6 FDA clearance for the Bria-BRES+ clinical study completes a busy two-week operational cadence for the company.
A Molecular Therapy Oncology 2026 paper from a multi-institution collaboration reported that a peptide engineered against Fibulin-4 — a glycoprotein overexpressed in metastatic breast cancer extracellular matrix — successfully targeted and killed metastatic breast cancer cells in mice. The same peptide doubles as an imaging probe, supporting peptide-based detection alongside therapy. The Fibulin-4 target is significant because metastatic breast cancer remains the leading cause of breast cancer mortality and current targeted therapies (HER2, hormone-receptor) leave a substantial therapy gap for triple-negative metastatic disease. The work joins the broader peptide-drug-conjugate field in which six PDCs are in Phase 3 trials and roughly 96 are in development, even as only Lutathera holds active FDA approval after the 2024 Pepaxto withdrawal.
BriaCell announced April 21 preclinical results from its next-generation Bria-OTS+ personalized peptide immunotherapy at the AACR 2026 Annual Meeting. The platform pairs HLA-matched whole-cell allogeneic immunotherapy with peptide-mediated antigen targeting, building on the Bria-IMT clinical foundation in heavily pretreated metastatic breast cancer. Based on the preclinical anti-cancer activity, BriaCell plans to enter the clinic for metastatic breast cancer and prostate cancer indications later in 2026, with lung cancer and melanoma planned for 2027. The program adds to a peptide-immuno-oncology pipeline that includes the Bria-IMT Phase 3 and the company's six accepted ASCO 2026 presentations covering survival data, biomarkers, and quality-of-life endpoints.
BriaCell announced April 27 that its Bria-IMT cell-based peptide immunotherapy will be featured in three poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago). Highlights include 12- and 24-month overall survival data with Bria-IMT plus checkpoint inhibition in advanced metastatic breast cancer, an updated quality-of-life and tolerability analysis, and a randomized Bria-ABC Phase 3 blood-biomarker progression-free survival readout. Three publication-only abstracts cover the second-generation BC1 platform, multi-analyte liquid biopsy stratification, and PD-L1 monitoring in circulating cancer-associated cells.